A process for assaying viral vector manufactured by large-scale viral vector manufacturing processes to assure the resulting vector has acceptable purity and potency. The process entails three different types of assays, each one of which is optionally useful on a stand-alone basis, and which together provide the first system able to assure the quality of viral vector produced by large-scale vector manufacturing processes.

The present invention relates to methods of producing porcine circovirus (PCV) pseudovirions in plant cells, the plant-produced PCV pseudovirions, a neutralisation assay using the plant-produced PCV pseudovirions and pharmaceutical compositions comprising the plant produced PCV pseudovirions. In particular, the method of the invention relates to introducing expression vectors, replicating vectors and nucleic acids into the plant cell and allowing for expression of capsid proteins and replication of the replicating vector. The expressed PCV capsid polypeptides assemble, together with a single-stranded copy of the replicating vector and encapsidate it as a pseudogenome to produce a PCV pseudovirion.

The instant disclosure provides methods of multi-assay processing and multi-assay analysis. Such multi-assay processing and analysis pertain to automated detection of target nucleic acids, e.g., as performed in the clinical setting for diagnostic purposes. Also provided are common assay timing protocols derived from a variety of individual nucleic acid amplification and analysis protocols and modified to prevent resource contention. The instant disclosure also provides systems and devices for practicing the methods as described herein.

A biosensor for detecting an influenza A virus in a sample is disclosed, which includes: an influenza A virus antibody immobilized on a surface of Au—Fe.sub.3O.sub.4 composite; where the antibody binds with the influenza A virus in the sample, which converts 4-methylumbelliferyl-N-acetyl-α-D-neuraminic acid (MUNANA) to 4-methylumbelliferone (4-MU), where the 4-MU emits green light at pH of 5.5-6.5; and wherein the 4-MU emits blue light at pH of 9.3-11.3. In the biosensor, 1,1′-oxalyldiimidazole chemiluminescence (ODI-CL) reagent may be utilized to emit the blue and green lights.

There is provided a method of detecting a microscopic body stored in a plurality of receptacles formed separately from each other. The method, which is provided as a technique for enclosing a to-be-detected substance such as nucleic acid, protein, virus, and cell by means of a simple operation in droplets of an extremely small volume and enabling highly sensitive detection, includes the steps of (1) introducing a solvent into a space between a lower layer part in which the receptacles are formed and an upper layer part facing a surface of the lower layer part in which surface the receptacles are formed, wherein the solvent contains the microscopic body; (2) introducing gas into the space to form a droplet of the solvent in the receptacles, wherein the droplet contains the microscopic body; and (3) detecting the microscopic body present in the droplet optically, electrically, and/or magnetically.

An examination system that recognizes a glycosylated antigen in Dane particles of hepatitis B virus (HBV) and a neutralizing antibody that recognizes the glycosylated antigen and that exhibits an infection-inhibiting activity. It was elucidated that Dane particles are associated with specific glycan structures, and this enabled the construction of a new detection system for infectious, i.e., nucleic acid-containing, hepatitis B virus particles and the provision of a neutralizing antibody that recognizes a glycosylated antigen and that exhibits an infection-inhibiting activity.

Provided are a virus measuring method, a virus measuring device, a virus determining program, a stress determining method, and a stress determining device. A virus measuring method includes a contact step of bringing a liquid specimen containing a body fluid of a subject and an electrolytic solution into contact with each other via a through-hole portion formed in a separating wall, a current measuring step of applying a voltage to the liquid specimen and the electrolytic solution with respect to the through-hole portion and obtaining a waveform of an ionic current flowing through the through-hole portion, and a virus determining step of determining the kind of a virus contained in the body fluid on the basis of the waveform. In the virus determining step, the kind of the virus is determined by comparing the waveform with waveform information that corresponds to a known virus and is obtained beforehand.

A kit, composition and method for detection of antibodies to severe acute respiratory syndrome related coronavirus (SARSr-CoV), and for diagnosis of SARSr-CoV infection.

This invention relates to soluble forms of G glycoprotein from Hendra and Nipah virus. In particular, this invention relates to compositions comprising soluble forms of G glycoprotein from Hendra and Nipah virus and also to diagnostic and therapeutic methods using the soluble forms of G glycoprotein from Hendra and Nipah virus. Further, the invention relates to therapeutic antibodies including neutralizing antibodies, and vaccines for the prevention and treatment of infection by Hendra and Nipah viruses.

The present invention provides systems, devices, and methods for point-of-care and/or distributed testing services. The methods and devices of the invention are directed toward automatic detection of analytes in a bodily fluid. The components of the device can be modified to allow for more flexible and robust use with the disclosed methods for a variety of medical, laboratory, and other applications. The systems, devices, and methods of the present invention can allow for effective use of samples by improved sample preparation and analysis.